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Abstract
Early linkage to care and antiretroviral (ARV) treatment are associated with reduced HIV
transmission. Male-to-male sexual contact represents the largest HIV transmission cate-
gory in the United States; men who have sex with men (MSM) are an important focus of
care and treatment efforts. With the release of the National HIV/AIDS Strategy and
expanded HIV treatment guidelines, increases in early linkage to care and ARV treatment
are expected. We examined differences in prevalence of early linkage to care and ARV treat-
ment among HIV-positive MSM between 2008 and 2011. Data are from the National HIV
Behavioral Surveillance System, which monitors behaviors among populations at high risk of
HIV infection in 20 U.S. cities with high AIDS burden. MSMwere recruited through venue-
based, time-space sampling. Prevalence ratios comparing 2011 to 2008 were estimated
using linear mixed models. Early linkage was defined as an HIV clinic visit within 3 months of
diagnosis. ARV treatment was defined as use at interview. Prevalence of early linkage to care
was 79% (187/236) in 2008 and 83% (241/291) in 2011. In multivariable analysis, prevalence
of early linkage did not differ significantly between years overall (P = 0.44). Prevalence of
ARV treatment was 69% (790/1,142) in 2008 and 79% (1,049/1,336) in 2001. In multivariable
analysis, ARV treatment increased overall (P = 0.0003) and among most sub-groups. Black
MSMwere less likely than white MSM to report ARV treatment (P = 0.01). While early linkage
to care did not increase significantly between 2008 and 2011, ARV treatment increased
among most sub-groups. Progress is being made in getting MSM on HIV treatment, but more
efforts are needed to decrease disparities in ARV coverage.
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Introduction
Men who have sex with men (MSM) are at increased risk of HIV infection and male-to-male
sexual contact represents the largest HIV transmission category in the United States. Of the
47,500 estimated incident HIV infections in the United States in 2010, 66% were estimated to
be among MSM, including MSM who inject drugs [1]. While the overall number of new HIV
infections in the United States remained stable between 2008 and 2010, new infections among
MSM increased 12%, from 26,700 in 2008 to 29,800 in 2010 [2]. Among MSM, blacks and Afri-
can Americans (hereafter referred to as blacks) are disproportionately affected by HIV. In
2010, black MSM accounted for 42% of all estimated incident HIV infections attributed to
male-to-male sexual contact [2]. Black HIV-positive MSM are less likely to be on treatment
compared to white MSM [3, 4], and such disparities in care and treatment among blacks may
contribute to higher HIV incidence rates [5].
Efforts to reduce HIV-related health disparities include improving access to care services
and increasing the proportion of MSM on antiretrovirals (ARV). Antiretrovirals lower HIV
viral load, improve health outcomes, and reduce the likelihood of HIV transmission [6]. Timely
linkage to care is a key step for initiation of ARV. In 2010, the White House released the
National HIV/AIDS Strategy (NHAS), a comprehensive plan with measurable HIV targets to
be achieved by 2015 [7]. These targets include increasing the proportion of newly diagnosed
persons linked to clinical care within three months of HIV diagnosis from 65% to 85%. The
NHAS also calls to increase the proportions of both HIV-diagnosed MSM and blacks with
undetectable viral load by 20%. In 2013, the HIV Care Continuum Initiative was established by
Presidential Executive Order to further focus implementation of the NHAS on activities to
address gaps along steps of the HIV continuum of care, including early linkage to care and
ARV treatment (Executive Order No. 13,649, 2013) [8].
Recommendations for initiating ARV in treatment-naïve persons have broadened over
time. While recommendations were initially restricted to persons with AIDS-defining illness or
a CD4 count less than 350 cells/mm3, guidelines were revised in 2009 to include those with a
CD4 count less than 500 cells/mm3 [9]. With additional data supporting improved outcomes
with early initiation of treatment [10, 11], ARV initiation was recommended for all HIV-
infected individuals in 2012 [9].
CDC’s National HIV Behavioral Surveillance System (NHBS) monitors HIV-associated
behaviors, including early linkage to care and ARV treatment, in MSM and other populations
at high risk of HIV infection [12]. In order to monitor progress toward the NHAS targets and
expanded treatment guidelines, we analyzed data from HIV-positive MSM from two cycles of
NHBS (2008 and 2011), to determine if there was a difference in prevalence of 1) early linkage
to care and 2) current ARV treatment between 2008 and 2011. We also examined differences
between the two time points in early linkage to care and ARV treatment by demographic char-
acteristics to quantify gaps and highlight progress in these two care measures.
Materials and Methods
NHBS monitors HIV-associated behaviors and HIV prevalence in 20 cities with high AIDS
burden among three populations at high risk for infection: MSM, injection drug users, and het-
erosexual adults at increased risk for HIV infection [12]. Cross-sectional behavioral data
reported in this analysis are fromMSM recruited for interviews and HIV testing through
venue-based, time-space sampling (VBS) in NHBS surveys in 2008 and 2011. NHBS VBS pro-
cedures have been previously published [12, 13] and are briefly summarized here. First, staff
identified venues frequented by MSM (e.g., bars, dance clubs, gyms, restaurants, parks, street
locations, and social organizations) and days and times when men frequented those venues. In
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2008, venues in which 75% of men attending were MSM were eligible for inclusion, while in
2011, this threshold was decreased to 50% due to more diverse venue attendee populations to
produce a comparable number of eligible venues in 2011. A comparison of the response rates
for the two years has been previously published [14]. Staff of funded sites determined venue eli-
gibility through secondary data review, interviews, focus groups, or observations. Second, ven-
ues and corresponding day-time periods were selected randomly for recruitment events. Third,
staff members systematically approached men at recruitment events to screen for eligibility
(aged 18 years, lived in a participating city, and able to complete the interview in English or
Spanish). In 2011, only men who reported ever having sex with another man were eligible.
Although eligibility criteria differed, the same analysis criteria were used for both years in this
analysis. Interviews were conducted by trained interviewers using a standardized questionnaire
covering demographics, HIV-associated behaviors, and use of HIV prevention and testing
services.
The two main outcomes in this analysis were early linkage to care and current ARV treat-
ment. Early linkage to care was defined as a reported clinic visit for HIV care within three
months of HIV diagnosis. HIV diagnosis date was ascertained from the questions “Before your
test in __/__ [most recent test], did you ever test positive for HIV?” and, if yes, “When did you
first test positive?” Early linkage to care was ascertained from the questions “Have you ever
been seen by a doctor, nurse, or other health care provider for a medical evaluation or care
related to your HIV infection?” and, if yes, “When did you first go to your health care provider
after learning you had HIV?” Analyses for early linkage to care were restricted to MSM diag-
nosed with HIV three or more months prior to NHBS interview. Early linkage to care analyses
were further restricted to those diagnosed with HIV in the three years prior to the study year
(2006–2008 for the 2008 study year and 2009–2011 for the 2011 study year). Since only indi-
viduals diagnosed after 2008 can contribute to a difference in early linkage to care between
2008 and 2011, data from both 2008 and 2011 were restricted to the three years prior to the
study year to create comparable samples. Current ARV treatment was defined as self-reported
use at the time of NHBS interview, as ascertained by the question “Are you currently taking
antiretroviral medicines to treat your HIV infection?” Self-reported HIV-positive MSM
(defined as ever had sex with a man) with complete and valid interview data were included in
analysis. Validity was assessed by the interviewer’s confidence in the respondent’s answers;
interviewers received in-person training on administering the questionnaire and interviews
they marked invalid were excluded from analysis. Confirmatory test results were not available
for 225 of 1,144 self-reported HIV-positive men in 2008 and 285 of 1,337 men in 2011 who
declined HIV testing; thus, self-reported HIV-positive status was used. A sensitivity analysis
that excluded men without a positive confirmatory test did not change study results. Data for
2008 were restricted to men who reported ever having sex with another man to match the 2011
eligibility criterion. Data came from the 20 cities that contributed NHBS data in both 2008 and
2011: Atlanta, GA; Baltimore, MD; Boston, MA; Chicago, IL; Dallas, TX; Denver, CO; Detroit,
MI; Houston, TX; Los Angeles, CA; Miami, FL; New Orleans, LA; Nassau-Suffolk, NY; New-
ark, NJ; New York, NY; Philadelphia, PA; San Diego, CA; San Francisco, CA; San Juan, PR;
Seattle, WA; and Washington, DC.
Unadjusted prevalence ratios comparing the outcomes in 2011 to 2008 were calculated to
explore differences over time by demographic characteristics (race, age, education, income,
and insurance). Because the goal of this analysis was to describe early linkage to care and ARV
treatment and how prevalence of these outcomes may have differed over time among demo-
graphic groups, behavioral and other risk factors were not considered. Adjusted prevalence
ratios were calculated from linear mixed models with a Poisson distribution and log link. Each
model included demographic characteristics and their interactions with year as fixed effects.
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City was included as a random effect to address correlated data within cities. The type of venue
where recruitment occurred (bar, dance club, or other) was also included in models as a fixed
effect to further account for some of the methodological complexities associated with VBS.
Analysis of racial disparities in prevalence of ARV treatment adjusted for other demographic
characteristics was conducted separately for 2008 and 2011 data and using combined 2008 and
2011 data. Model-adjusted prevalence of ARV treatment by racial category was estimated
using ESTIMATE statements in SAS. All analyses were conducted using SAS 9.3 (SAS Institute
Inc., Cary, NC, USA).
Activities for NHBS were approved by local institutional review boards (IRB) for each of the
20 participating cities. NHBS activities were determined to be research in which the Centers for
Disease Control and Prevention was not directly engaged and, therefore, did not require review
by CDC IRB. All participants were explicitly assured during the recruitment process of the
anonymous nature of the survey and the HIV testing. No personal identifiers were collected
during enrollment, interview, or testing. All participants provided oral informed consent to
take part in the interview and to be tested for HIV. Oral consent was documented electronically
on the survey instrument by interviewers for all participants and on hard copy as required by
local IRBs. Because data collection was anonymous, written consent was not possible and par-
ticipant names or other personal identifiers were not linked to any NHBS instruments. All con-
sent procedures, including verbal consent, were approved by local IRBs (Table 1).
Results
Data on NHBS recruitment in 2008 and 2011 are presented elsewhere [14]. Of 9,463 MSM
who consented and had valid and complete interviews in 2008, 1,144 (12.1%) reported being
HIV-positive. Of 9,819 MSM who consented and had valid and complete interviews in 2011,
1,337 (13.6%) reported being HIV-positive. Men included in the analysis sample differed by
race between 2008 and 2011 (Table 2). While the proportion that was white decreased 8%
between 2008 and 2011, the proportion that was black increased 7%. Men included in the 2011
sample were slightly younger than those in the 2008 sample and were more likely to have been
diagnosed with HIV at a younger age. Education, income, and health insurance status were
similar between the two years. More than half of men in 2008 were recruited at bars (52%),
with fewer men recruited at other venues (33%) and dance clubs (15%). In 2011, the proportion
of men recruited at bars and other venues was comparable (42% vs. 41%), with 17% recruited
at dance clubs.
For the early linkage to care analysis, 52 MSM in 2008 and 57 men in 2011 were diagnosed
with HIV in the three months prior to the NHBS interview and were excluded. An additional
20 MSM in 2008 and 17 MSM in 2011 were excluded because they were diagnosed in the same
year as the interview and had an unknown month of diagnosis. Two men in 2008 were missing
data on first visit for HIV care. After excluding 833 men diagnosed before 2006 in the 2008
sample and 968 men diagnosed before 2008 in the 2011 sample, 236 men in 2008 and 291 men
in 2011 were included in analyses (Table 3). In both years, early linkage to care was more likely
among those with higher education and income and with current insurance. Overall, preva-
lence of early linkage to care did not differ over time (79% in 2008 and 83% in 2011, P = 0.44).
In addition, early linkage to care did not differ among demographic sub-groups between 2008
and 2011. Early linkage to care was reported by a higher proportion of black MSM in 2011
(83%) than 2008 (72%), but this increase was not statistically significant (P = 0.11). Multivari-
able analyses were not done due to the lack of statistical significance of bivariate analyses.
For the current ARV treatment analysis, all self-reported HIV-positive MSM interviewed in
2008 (n = 1,144) and 2011 (n = 1,337) were eligible for inclusion. Two MSM in 2008 and one
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MSM in 2011 were missing data on current ARV treatment, leaving 1,142 in 2008 and 1,336 in
2011 for the analysis (Table 4). In both years, a higher percentage of ARV treatment was
observed among whites, older age groups, MSM with higher education and income, and those
with health insurance. Overall, prevalence of ARV treatment increased from 69% in 2008 to
79% in 2011 (P<0.0001). ARV treatment also increased among most race/ethnicity groups,
younger age groups (<40 years), and MSM with higher education. Increases in ARV treatment
were seen across income and insurance groups. There was a significant racial disparity between
white and black MSM in current ARV treatment in both years (Fig 1). Whites were 19% more
likely than blacks to report current ARV treatment when data for 2008 and 2011 were com-
bined (P<0.001). In the multivariable analysis, whites were 9% more likely than blacks to
report current ARV treatment (P = 0.01). Separate analysis of 2008 and 2011 data produced
similar results (data not shown).
Data on ARV use in the continuum of care are often presented among those retained in
HIV care (the previous step in the continuum). While we did not make this restriction in our
Table 1. Approving Institutional Review Boards (IRBs) for NHBS-MSM Activities (2008 and 2011).
City Approving IRB
Atlanta Georgia Department of Human Resources IRB (2008 only)
Emory University IRB (2008 only)
Georgia Department of Public Health (2011 only)
Georgia Department of Community Health (2011 only)
Baltimore Maryland Department of Health and Mental Hygiene IRB
Johns Hopkins Bloomberg School of Public Health IRB
Boston Massachusetts Department of Public Health Human Research Review Committee
Boston University Medical Center IRB (2011 only)
Chicago Chicago Department of Public Health IRB
Dallas Texas Department of State Health Services IRB
Texas A&M University Office of Research Compliance
Denver Colorado Multiple IRB
Detroit Michigan Department of Community Health IRB
Houston Univ. of Texas Health Science Center Committee for the Protection of Human Subjects
Los Angeles County of Los Angeles Public Health IRB
Miami Florida Department of Health IRB
University of Miami IRB (2008 only)
Nassau State of New York Department of Health IRB
New Orleans State of Louisiana Department of Health and Hospitals IRB
Louisiana State University Health and Sciences Center IRB
New York City New York City Department of Health and Mental Hygiene IRB
National Development and Research Institute IRB (2008 only)
John Jay College of Criminal Justice IRB (2011 only)
Newark State of New Jersey Department of Health and Senior Services IRB
Philadelphia City of Philadelphia Department of Public Health IRB
San Francisco Univ. of California, San Francisco Committee on Human Research
San Juan Univ. of Puerto Rico, Medical Sciences Campus IRB
San Diego California Health and Human Services Agency Committee for the Protection of Human
Subjects
Seattle State of Washington Department of Social and Health Services IRB
Washington,
DC
Government of the District of Columbia Department of Health IRB
George Washington University Medical Center IRB
doi:10.1371/journal.pone.0132962.t001
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Table 2. Characteristics of HIV-positive men who have sex with men–NHBS, 2008 and 2011.
Characteristic 2008 2011
n (%) n (%)
Total 1,144 1,338
Race/Ethnicity
Black 292 (25.5) 446 (33.5)
Hispanic/Latino 243 (21.2) 278 (20.9)
White 543 (47.5) 528 (39.6)
Otherb 66 (5.8) 80 (6.0)
Current age (years)
18–29 205 (17.9) 325 (24.3)
30–39 327 (28.6) 328 (24.5)
40–49 405 (35.4) 442 (33.0)
50 207 (18.1) 243 (18.2)
Education
Less than high school 88 (7.7) 86 (6.4)
High school diploma or equivalent 277 (24.2) 309 (23.1)
Some college 414 (36.2) 504 (37.7)
College or higher 365 (36.5) 438 (32.8)
Annual household income
0 to $19,999 439 (38.6) 525 (39.7)
$20,000 to $39,999 262 (23.0) 344 (26.0)
$40,000 to $74,999 236 (20.7) 270 (20.4)
$75,000 or more 201 (17.7) 183 (13.9)
Current health insurance
No 282 (24.7) 277 (20.7)
Yes 862 (75.4) 1,060 (79.3)
Years since HIV diagnosis
 5 years from interview date 476 (42.4) 574 (43.5)
6–10 years from interview date 201 (17.9) 248 (18.8)
> 10 years from interview date 447 (39.8) 499 (37.8)
Age at HIV diagnosis (years)
 24 265 (23.6) 418 (31.6)
25–29 274 (24.4) 295 (22.3)
30–39 410 (36.5) 414 (31.3)
 40 175 (15.6) 194 (14.7)
Venue typec
Bar 596 (52.1) 565 (42.2)
Dance club 172 (15.0) 222 (16.6)
Otherd 376 (32.9) 551 (41.2)
City
Atlanta, Georgia 14 (1.2) 100 (7.4)
Baltimore, Maryland 52 (4.6) 60 (4.5)
Boston, Massachusetts 32 (2.7) 44 (3.3)
Chicago, Illinois 59 (5.2) 83 (6.2)
Dallas, Texas 73 (6.5) 105 (7.9)
Denver, Colorado 106 (9.3) 80 (6.0)
Detroit, Michigan 38 (3.3) 55 (4.1)
Houston, Texas 98 (8.6) 73 (5.5)
(Continued)
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analysis, we present these data in order to compare our ARV use prevalence to other studies.
When the sample of MSM was restricted to those who reported being retained in care (defined
as an MD visit for HIV in the 6 months prior to interview, n = 905 in 2008 and n = 1,101 in
2011), the prevalence of ARV use was 79% in 2008 and 87% in 2011 (P<0.0001) (data not
shown), a similar increase to the unrestricted analysis.
Discussion
While the prevalence of early linkage to care among MSM did not increase significantly
between 2008 and 2011, the prevalence of ARV treatment increased 10% overall and among
most demographic groups. These data suggest that those who have linked to care are increas-
ingly initiating ARV, in accordance with the more inclusive guidelines introduced in 2009.
There is a large disparity between black and white MSM with respect to current ARV treat-
ment despite similar prevalence for early linkage to care between the two groups. Studies have
demonstrated that black HIV-positive individuals are less likely than whites to be prescribed
ARV and to adhere to ARV regimens once prescribed [15–18]. The adjusted 9% difference in
prevalence of ARV treatment between black and white MSM in the NHBS sample is similar to
a 7% difference (adjusted for age, lapse in health coverage, poverty, time since diagnosis, and
disease stage) described among black and white MSM attending 461 US care facilities in the
Medical Monitoring Project [19]. These disparities are much lower than those described in a
meta-analysis of three quantitative studies of MSM done prior to 2003 that stratified ARV
treatment by race [4]. That analysis found that HIV-positive black MSM were 57% less likely
to report taking ARV compared to white MSM (OR: 0.43, 95% CI: 0.30–0.61), although the
contributing studies were small or nonrepresentative and were not adjusted for age and other
covariates. While the disparity among MSM is smaller in NHBS, it is worth noting that it did
not improve between the 2008 and 2011 data collection cycles.
Table 2. (Continued)
Characteristic 2008 2011
n (%) n (%)
Los Angeles, California 71 (6.2) 77 (5.8)
Miami, Florida 77 (6.7) 84 (6.3)
Nassau-Suffolk, New York 20 (1.8) 13 (1.0)
Newark, New Jersey 73 (6.5) 66 (4.9)
New Orleans, Louisiana 12 (1.1) 39 (2.9)
New York, New York 93 (8.1) 76 (5.7)
Philadelphia, Pennsylvania 33 (2.9) 50 (3.7)
San Diego, California 77 (6.7) 74 (5.5)
San Francisco, California 96 (8.4) 110 (8.2)
San Juan, Puerto Rico 14 (1.2) 10 (0.8)
Seattle, Washington 52 (4.6) 72 (5.4)
Washington, D.C. 55 (4.8) 67 (5.0)
Numbers may not add to total due to missing values.
aHispanic/Latinos can be of any race
bIncludes MSM reporting American Indian or Alaska Native, Asian, Native Hawaiian or Pacific Islander, other race, or multiple races
c Venue type refers to the type of venue where the participant was recruited
dOther venues include gyms, restaurants, parks, street locations, social organizations, and other places where MSM congregate
doi:10.1371/journal.pone.0132962.t002
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Our data also show a disparity between younger and older MSM. Younger MSM were much
less likely to be on ARVs compared to older MSM (57% among those< 30 years vs. 86%
among those 30 years in 2011). Maximizing care and treatment for young MSM is important
as HIV case surveillance data show that the only age group among MSM for which new HIV
infections increased from 2008 to 2010 was MSM aged 13 to 24 years [2]. While racial dispari-
ties in HIV prevalence and treatment have been widely described since the early years of the
epidemic [20, 21], recent data show alarming rates of HIV infection among young MSM, espe-
cially young blacks [22].
The prevalence of early linkage to care among this sample of MSM was relatively high, at
83% in 2011. This estimate is similar to an analysis of early linkage to care among MSM in the
U.S. for 2009, which estimated that 80% of MSM were linked to care within three months of
diagnosis [5]. Both analyses suggest that the NHAS goal of 85% linked to care early by 2015 is
feasible among HIV-positive MSM. Estimates of ARV use among NHBS MSM retained in care
are also comparable to Hall et al (87% among NHBS MSM compared to 90% among MSM in
Hall et al) [5]. Our estimate may be slightly lower due to a higher prevalence of young MSM in
our sample, who were less likely to be on ARVs.
Table 3. Prevalence of early linkage to HIV care and prevalence ratios comparing prevalence of early linkage to carea in 2011 to 2008 amongmen
who have sex with men–NHBS.
Characteristic 2008 2011
No. in sample n (%) No. in sample n (%) Unadjustedb PR (95% CI) P-value
Overall 236 187 (79.2) 291 241 (82.8) 1.05 (0.93–1.18) .44
Race/Ethnicity
Black 72 52 (72.2) 119 99 (83.2) 1.15 (0.96–1.38) .11
Hispanic/Latinoc 53 42 (79.3) 61 54 (88.5) 1.12 (0.96–1.30) .15
White 90 77 (85.6) 91 74 (81.3) 0.90 (0.55–1.48) .66
Otherd 21 16 (76.2) 19 13 (68.4) 0.95 (0.81–1.11) .51
Age at HIV diagnosis (years)
 24 61 48 (78.7) 116 95 (81.9) 1.04 (0.85–1.27) .69
25–29 50 37 (74.0) 52 43 (82.7) 1.12 (0.89–1.40) .32
30–39 74 56 (75.7) 72 62 (86.1) 1.14 (0.91–1.43) .26
 40 51 46 (90.2) 51 41 (80.4) 0.89 (0.74–1.07) .20
Education
High school or less 85 66 (77.7) 105 81 (77.1) 0.99 (0.86–1.15) .93
More than high school 151 121 (80.1) 186 160 (86.0) 1.07 (0.94–1.23) .28
Annual household income
$0 to $19,999 92 70 (76.1) 147 119 (81.0) 1.06 (0.92–1.23) .37
$20,000 143 117 (81.1) 142 120 (84.5) 1.03 (0.90–1.19) .63
Current insurance
No 85 64 (75.3) 86 62 (72.1) 0.96 (0.77–1.19) .67
Yes 151 123 (81.5) 205 179 (87.3) 1.07 (0.95–1.21) .23
Abbreviations: CI, confidence interval; MSM, men who have sex with men; PR, prevalence ratio
aDefined as a self-reported clinic visit for HIV care within three months of HIV diagnosis, restricted to those diagnosed with HIV in the three years prior to
the study year (2006–2008 for the 2008 study year and 2009–2011 for the 2011 study year)
bReference is 2008; PR corresponds to the interaction term with year; city is included as a random effect
cHispanic/Latinos can be of any race
dIncludes MSM reporting American Indian or Alaska Native, Asian, Native Hawaiian or Pacific Islander, other race, or multiple races
doi:10.1371/journal.pone.0132962.t003
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Ongoing changes in the U.S. health-care system offer opportunities to improve use of clini-
cal preventive services by MSM. The Patient Protection and Affordable Care Act of 2010 (as
amended by the Healthcare and Education Reconciliation Act of 2010 and referred to collec-
tively as the Affordable Care Act [ACA]) expands insurance coverage, consumer protections,
and access to primary care and emphasizes prevention in addition to care and treatment (see
http://aids.gov/federal-resources/policies/health-care-reform/). Under the ACA, most new
health insurance plans must cover HIV testing for everyone aged 15 to 65 without additional
cost-sharing, such as copays or deductibles (payments made by the beneficiary). In addition,
many HIV-infected MSM are newly eligible for Medicaid coverage and others are eligible to
purchase private insurance through the marketplaces (websites where individuals can compare
insurance plans and enroll in coverage) [23]. However, significant barriers to care continue, as
HIV-infected MSM will remain uninsured if they reside in a state that is not expanding Medic-
aid [24]. Many of the states that did not expand Medicaid are located in the southern U.S.,
where prevalence of HIV is higher. In addition, subsidies for private coverage are not available
Table 4. Prevalence of current ARV treatment and prevalence ratios comparing prevalence of current ARV treatment in 2011 to 2008 amongMSM–
NHBS.
Characteristic 2008 2011
No. in
sample
n (%) No. in
sample
n (%) Unadjusteda PR
(95% CI)
P-
value
Adjustedb PR
(95% CI)
P-
value
Overall 1,142 790 (69.2) 1,336 1,049 (78.5) 1.14 (1.08–1.19) < .0001 1.20 (1.11–1.31) .0003
Race/Ethnicity
Black 291 177 (60.8) 444 315 (71.0) 1.17 (1.04–1.31) .01 1.25 (1.09–1.42) .001
Hispanic/Latinoc 243 170 (70.0) 278 220 (79.1) 1.13 (1.00–1.27) .04 1.22 (1.08–1.39) .002
White 542 400 (73.8) 528 453 (85.8) 1.16 (1.10–1.23) .44 1.29 (1.16–1.44) < .0001
Otherd 66 43 (65.2) 80 56 (70.0) 1.07 (0.89–1.29) < .0001 1.05 (0.86–1.29) .63
Current age (years)
18–29 205 78 (38.1) 323 185 (57.3) 1.51 (1.22–1.86) .0003 1.46 (1.22–1.76) .0001
30–39 325 205 (63.1) 328 258 (78.7) 1.25 (1.11–1.40) .0003 1.24 (1.07–1.42) .004
40–49 405 334 (82.5) 442 386 (87.3) 1.06 (0.99–1.13) .08 1.06 (0.95–1.19) .29
 50 207 173 (83.6) 243 220 (90.5) 1.08 (1.00–1.18) .06 1.08 (0.96–1.21) .19
Education
High school or less 364 238 (65.4) 395 285 (72.2) 1.10 (0.99–1.23) .07 — —
More than high school 778 552 (71.0) 940 763 (81.2) 1.14 (1.07–1.22) .0006 — —
Annual household
income
$0 to $19,999 437 290 (66.4) 524 384 (73.3) 1.10 (1.01–1.21) .04 1.18 (1.06–1.31) .005
$20,000 699 495 (70.8) 796 652 (81.9) 1.16 (1.10–1.22) < .0001 1.22 (1.12–1.34) .0002
Current insurance
No 281 142 (50.5) 277 167 (60.3) 1.19 (1.00–1.43) .05 1.23 (1.06–1.42) .008
Yes 861 648 (75.3) 1,058 881 (83.3) 1.11 (1.07–1.15) < .0001 1.17 (1.10–1.24) < .0001
Abbreviations: ARV, antiretroviral; CI, confidence interval; MSM, men who have sex with men; PR, prevalence ratio
aReference is 2008; PR corresponds to the interaction term with year
bReference is 2008; PR corresponds to the interaction term with year; model includes year, race/ethnicity, current age, annual household income, current
insurance, venue type where recruitment occurred (bar, dance club, or other), and their interactions with year as fixed effects; city is included as a random
effect
cHispanic/Latinos can be of any race
dIncludes MSM reporting American Indian or Alaska Native, Asian, Native Hawaiian or Pacific Islander, other race, or multiple races.
doi:10.1371/journal.pone.0132962.t004
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to people with incomes below 100 percent of poverty, so many HIV-infected MSMmay not
qualify for these subsidies [22].
Our analyses are subject to several limitations. First, NHBS is not a nationally representative
sample, so results may not be generalizable to all cities or to all MSM in participating cities.
Our population of inference is limited to MSM who reside in and attend MSM venues in the
NHBS cities. Second, our data are collected through face-to-face interviews and our measures
of early linkage to care and ARV treatment are based on self-reported data and might be sub-
ject to social desirability and recall bias. Social desirability would lead to overestimation of
prevalence estimates, while the direction of bias due to recall error is unknown. However, our
results are based on differences between 2008 and 2011 and are less likely to be affected by
these biases than the point estimates themselves provided the biases remained consistent over
time. The data are also subject to variability related to interviewer reliability and skill. There
were differences in eligibility in 2008 and 2011 but the same analysis criteria were used for both
years. The NHBS questionnaire has undergone minor updates between MSM cycles, but the
items used to determine early linkage to care and ARV use were identical in 2008 and 2011. In
addition, this is a cross-sectional analysis that does not permit inference regarding causation.
Fig 1. Adjusted prevalencea of current ARV treatment by race/ethnicity amongMSM—NHBS, 2008 and 2011. Adjusted prevalences from a model
adjusted for year, current age, annual household income, current insurance, venue type where recruitment occurred, and city (random effect) show that the
percent of blacks currently on antiretroviral therapy is significantly less than the percent of whites currently on antiretroviral therapy in both years. aAdjusted
prevalence estimated from the following model: current ARV = α + β1*race + β 2*age + β 3*current insurance + β 4*income + β 5*venue type + β 6*year + β
7*race*year + β 8*age*year + β 9*current insurance*year + β 10*income*year; city is included as a random effect; adjusted prevalence ratio based on
combined 2008, 2011 data comparing whites to blacks was 1.09 (CI: 1.02–1.16); bHispanics can be of any race; cIncludes MSM reporting American Indian or
Alaska Native, Asian, Native Hawaiian or Pacific Islander, other race, or multiple races.
doi:10.1371/journal.pone.0132962.g001
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The analysis is limited to two time points and cannot be interpreted as a trend nor as resulting
from changes to policy or practices that occurred between these time points. Our analysis also
did not include data on ARV adherence or viral load suppression, so we cannot say whether
MSM currently on ARV are at reduced risk of HIV transmission. We therefore do not have
viral suppression data to compare to the NHAS goals for MSM overall and among black MSM.
Finally, data are not weighted to account for the complex sampling methodology used to
recruit MSM. Point estimates may therefore be biased by over- or under-represented sub-
groups of the sample. Therefore, the point estimates should be interpreted with caution, espe-
cially those for the total sample. However, multivariate analysis of differences across years
should not be affected by a lack of weighting, especially given the consistency of data distribu-
tion between 2008 and 2011 [25].
In summary, our analysis demonstrated a significant increase in ARV treatment between
2008 and 2011 among HIV-positive MSM, encompassing a time period when the National
HIV/AIDS Strategy was introduced and treatment guidelines were expanded. While there was
not an increase in early linkage to care between 2008 and 2011, the high prevalence of early
linkage to care is encouraging, especially with the increasing evidence supporting treatment as
prevention and expanded treatment guidelines released in 2012. Efforts are needed, however,
to decrease barriers to ARV provision and adherence among black MSM in order to reduce the
present disparity in treatment.
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